1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

BioNotebook: Trevi, Complexa raise VC cash; Deerfield commits $60m to KemPharm; Aradigm, Voyager deal news; IPO updates

 
• By Mandy Jackson

The second quarter of 2014 started off with a surge in venture capital deals, but the momentum seems to have slowed a bit as the quarter gets closer to its end, with the exception of Trevi Therapeutics and Complexa, which recently announced a total of $38m in new capital.

The second quarter of 2014 started off with a surge in venture capital deals, but the momentum seems to have slowed a bit as the quarter gets closer to its end, with the exception of Trevi Therapeutics and Complexa, which recently announced a total of $38m in new capital.

Perhaps funding news slowed during the last half of May and the first week of June because the biopharma industry was focused on data instead of dollars in the lead-up to the 50th Annual American Society of Clinical Oncology (ASCO) Meeting from 31 May to 3 June in Chicago. But there's still plenty of time left in June for venture capital to end the second quarter with a three-month total that exceeds the $1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Therapy Areas

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.